Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Supplement use was also markedly higher in IBD patients, with vitamin D and iron supplementation being significantly more common in both UC and CD groups than in HC (p < 0.01) (Table 1).

Source: Cohort characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

In this cohort study, three groups of adult participants were enrolled (aged ≥ 18 years), UC (n = 31), CD (n = 39), and healthy individuals (n = 49) as a control group.

Source: Methods.

In this cohort study, three groups of adult participants were enrolled (aged ≥ 18 years), UC (n = 31), CD (n = 39), and healthy individuals (n = 49) as a control group.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease

Cohort study · Frontiers in Microbiology · 2026

Original publication title

Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease

Omer Sabti; Ksenia Lialin-Tzadikov; Valeria Ivanova; Mally Dori-Bachash; Shaked Uzi-Gavrilov; Zohar Tik; Roi Mashiach; Alvah Zorea; Itzhak Mizrahi; Arik Segal; Keren Moyal-Attias; Eran Elinav; Michael M. Meijler

Copyright © 2026 Sabti, Lialin-Tzadikov, Ivanova, Dori-Bachash, Uzi-Gavrilov, Tik, Mashiach, Zorea, Mizrahi, Segal, Moyal-Attias, Elinav and Meijler.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: What background does the paper provide?

The gut microbiome mediates the reductive catabolism of bilirubin into urobilinoids, yet the bacteria and enzymes responsible for the later steps of this pathway remain largely unknown.

Source: Background

Abstract: What methods does the paper describe?

Here, we combine untargeted UPLC/HRMS metabolomics with shotgun metagenomic sequencing of fecal samples from 119 participants, including patients with Crohn’s disease, ulcerative colitis, and healthy controls, to map disruptions in the bilirubin catabolic pathway in inflammatory bowel disease (IBD).

Source: Methods

Abstract: Discussion

These findings implicate Lachnospiraceae as key mediators of the yet unknown enzymatic conversion of I-urobilinogen to stercobilinogen, extending the family’s known metabolic repertoire beyond short-chain fatty acid production. Given that bilirubin and its reduced metabolite stercobilinogen possess antioxidant properties, their depletion may contribute to the oxidative burden in the IBD gut. Conversely, the concurrent elevation of D-urobilin, which lacks these protective properties and has been linked to metabolic dysfunction in other contexts, may further exacerbate inflammation. Our results identify fecal bilirubin metabolites as candidate biomarkers of microbial dysbiosis in IBD and nominate specific Lachnospiraceae taxa for functional characterization of the missing stercobilinogen reductase.

Source: Discussion

Abstract: Results

We show that stercobilinogen and stercobilin, the terminal metabolites of this pathway, are depleted (p < 0.01) in IBD patients irrespective of disease subtype, while upstream intermediates, D-urobilinogen, remain unchanged. This metabolic bottleneck coincides with a marked reduction in members of the Lachnospiraceae family, specifically Blautia sp. SG-772 and three uncharacterized species, which show strong positive correlations with stercobilinogen and stercobilin levels.

Source: Results
Authors’ abstract

Background

The gut microbiome mediates the reductive catabolism of bilirubin into urobilinoids, yet the bacteria and enzymes responsible for the later steps of this pathway remain largely unknown.

Methods

Here, we combine untargeted UPLC/HRMS metabolomics with shotgun metagenomic sequencing of fecal samples from 119 participants, including patients with Crohn’s disease, ulcerative colitis, and healthy controls, to map disruptions in the bilirubin catabolic pathway in inflammatory bowel disease (IBD).

Results

We show that stercobilinogen and stercobilin, the terminal metabolites of this pathway, are depleted (p < 0.01) in IBD patients irrespective of disease subtype, while upstream intermediates, D-urobilinogen, remain unchanged. This metabolic bottleneck coincides with a marked reduction in members of the Lachnospiraceae family, specifically Blautia sp. SG-772 and three uncharacterized species, which show strong positive correlations with stercobilinogen and stercobilin levels.

Discussion

These findings implicate Lachnospiraceae as key mediators of the yet unknown enzymatic conversion of I-urobilinogen to stercobilinogen, extending the family’s known metabolic repertoire beyond short-chain fatty acid production. Given that bilirubin and its reduced metabolite stercobilinogen possess antioxidant properties, their depletion may contribute to the oxidative burden in the IBD gut. Conversely, the concurrent elevation of D-urobilin, which lacks these protective properties and has been linked to metabolic dysfunction in other contexts, may further exacerbate inflammation. Our results identify fecal bilirubin metabolites as candidate biomarkers of microbial dysbiosis in IBD and nominate specific Lachnospiraceae taxa for functional characterization of the missing stercobilinogen reductase.

Publication and source details

Original title: Disrupted terminal bilirubin catabolism links Lachnospiraceae depletion to inflammatory bowel disease

Omer Sabti; Ksenia Lialin-Tzadikov; Valeria Ivanova; Mally Dori-Bachash; Shaked Uzi-Gavrilov; Zohar Tik; Roi Mashiach; Alvah Zorea; Itzhak Mizrahi; Arik Segal; Keren Moyal-Attias; Eran Elinav; Michael M. Meijler

Frontiers in Microbiology · 2026

* Correspondence: Michael M. Meijler, meijler@bgu.ac.il
†

ORCID: Alvah Zorea, orcid.org/0000-0001-6543-2259

Copyright © 2026 Sabti, Lialin-Tzadikov, Ivanova, Dori-Bachash, Uzi-Gavrilov, Tik, Mashiach, Zorea, Mizrahi, Segal, Moyal-Attias, Elinav and Meijler.2026Sabti, Lialin-Tzadikov, Ivanova, Dori-Bachash, Uzi-Gavrilov, Tik, Mashiach, Zorea, Mizrahi, Segal, Moyal-Attias, Elinav and Meijlerhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This study was supported by grants from the Israel Science Foundation (MMM Grants #1485/20, 2170/24) and the Deutsche Forschungsgemeinschaft (MMM and EE Germany-Israel Project Grant DIP ME4476/2).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:54:14.165690+00:00

DOI: 10.3389/fmicb.2026.1871609 · PMC13526984